| Description | Maralixibat Chloride (LUM001 chloride), an apical, sodium-dependent, bile acid transport inhibitor, prevents enterohepatic bile acid recirculation. |
| In vivo | Maralixibat chloride can increase the level of sBA and reduce liver injury in cholestatic rats by partial bile duct ligation[1]. |
| Target activity | Ileal sodium-dependent bile acid transporters:0.89 μM |
| Synonyms | SHP-625, SHP625, Livmarli, LUM001 chloride, Lopixibat chloride, Lopixibat, SHP625 chloride, SHP 625 |
| molecular weight | 710.41 |
| Molecular formula | C40H56ClN3O4S |
| CAS | 228113-66-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 35 mg/mL (49.27 mM), Sonication is recommended. |
| References | 1. Kurata, Hitoshi; Bioorganic & Medicinal Chemistry Letters (2004), 14(5), 1183-1186 |